CTOs on the Move

MedPharm

www.medpharm.com

 
MedPharm is a world-leading contract provider of topical and transdermal product design and development services. Our delivery of robust and innovative research has commanded recognition from regulators and investors alike. We utilise our unique cost-effective performance testing models to mitigate risk and accelerate development times.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.medpharm.com
  • 4222 Emperor Boulevard Suite 335
    Durham, NC USA 27703
  • Phone: 919.436.4985

Executives

Name Title Contact Details
Dave Haas
Vice President Information Technology Profile
Jon Lenn
Chief Technology Officer and Chief Scientific Officer Profile

Similar Companies

Qserve Group

Qserve is your MedTech Partner for Regulatory & Quality Affairs and Clinical Trials. Need regulatory advice, support or training? Contact us.

CORIA Laboratories

CORIA Laboratories, Ltd. is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CardioRisk

CardioRisk is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Prospect Biosystems

Prospect Biosystems is a Newark, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Ionis Pharmaceuticals

For more than 30 years, Ionis has been the leader in RNA-targeted therapy, pioneering new markets and changing standards of care with its novel antisense technology. Ionis currently has three marketed medicines and a premier late-stage pipeline highlighted by industry-leading cardiovascular and neurological franchises. Our scientific innovation began and continues with the knowledge that sick people depend on us, which fuels our vision of becoming a leading, fully integrated biotechnology company. Our drug discovery platform has served as a springboard for actionable promise and realized hope for patients with unmet needs. We created the first and only approved treatment for children and adults with spinal muscular atrophy as well as the world`s first RNA-targeted therapeutic approved for the treatment of polyneuropathy in adults with hereditary transthyretin amyloidosis.